Rangaswamy Govindarajan, MD

Research Program: Cancer Therapeutics Faculty Rank: Professor Campus: University of Arkansas for Medical Sciences College: College of Medicine Department: Internal Medicine

Cancer Research Interest

• Disease Site Focus: GI, Sarcoma
• Research Focus Area: Informatics, Treatment, Diagnosis/ Prognosis
• Type of Research: Clinical

Contact Information

• Email Address: GOVINDARAJANRANG@UAMS.EDU
• Profiles Research Networking Software: View Profile

Open Clinical Trials

• “S2303, Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel +Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS = 1Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE).” (NCT06203600)
• “OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy” (NCT05812807)
• “Pragmatica - Lung: A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) Plus Pembrolizumab (MK-3475; NSC 776864) Versus Standard of Care for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer” (NCT05633602)
• “Pragmatica - Lung: A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) Plus Pembrolizumab (MK-3475; NSC 776864) Versus Standard of Care for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer” (NCT05633602)
• “Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation” (NCT04566328)
• “S2010 A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone To Improve Persistence With Endocrine Therapy In Young Women With Stage I-III Breast Cancer (ASPEN)” (NCT02506153)
• “S2013 Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study” (NCT04871542)
• “S1703 Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive HER-2 Negative Breast Cancer” (NCT03723928)

Recent Publications

• Algazi AP, Othus M, Daud AI, [et al., including Govindarajan R]. Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial. Nature medicine. 2020 26(10):1564-1568. PMID: 33020646. PMCID: PMC8063889.